<DOC>
	<DOCNO>NCT02703454</DOCNO>
	<brief_summary>The study design prospective , multicenter , single-blind , randomize study ass safety effectiveness FIRM-guided radiofrequency ( RF ) ablation procedure treatment symptomatic PAF . The subject blind study treatment duration study period .</brief_summary>
	<brief_title>FIRM Ablation Versus Pulmonary Vein Isolation Treatment Paroxysmal Atrial Fibrillation ( PAF )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Key Experiencing least two ( 2 ) document episode paroxysmal atrial fibrillation last 3 month precede study entry clinical indication AF ablation per guideline . At least one episode document rhythm strip ECG . Indicated AF ablation accord current EHRA guideline . Prescribed oral anticoagulation therapy , indicate patient per late EHRA guideline . Willingness able remain anticoagulation therapy per late EHRA guideline . Left atrial diameter &lt; 5.5 cm measure image ( ( CT/TEE/TTE/ MRI ICE ) document within previous six month preprocedure . Sustained AF ( &gt; 5 min uninterrupted ) electrophysiology procedure . If subject experience spontaneous , sustained AF , may induce burst pacing ( typically coronary sinus ) without isoproterenol infusion conventional clinical fashion . Key NYHA Class III IV . Ejection fraction &lt; 40 % ( within previous six month ) . History myocardial infarction ( MI ) within past three month . Any concomitant arrhythmia therapy could interfere interpretation result study . ASD closure device , LAA closure device , prosthetic mitral tricuspid valve , permanent pacemaker . Any previous AF catheter ablation . History prior cardioversion AF last &gt; 48 hour . Continuous AF episode last &gt; 7 day immediately prior procedure without sinus rhythm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>